Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Darla Miller
Observed institutions:
University of North Carolina at Chapel Hill,
The University of Texas MD Anderson Cancer Center
ORCID:
0009-0001-3183-1654
Observed ORCID:
0009-0001-3183-1654
OpenAlex ID:
A5000855145
Content and Performance of the MiniMUGA Genotyping Array: A New Tool To Improve Rigor and Reproducibility in Mouse Research
2020
·
John Sebastian Sigmon
, Matthew W Blanchard
, et al.
·
Genetics
·
93
PDF
Phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents
2016
·
Elias Jabbour
, Stefan Faderl
, et al.
·
Cancer
·
35
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia
2022
·
Nicholas J. Short
, Gautam Borthakur
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
26
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2023
·
Jayastu Senapati
, Warren C. Fiskus
, et al.
·
Clinical Cancer Research
·
25
Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium
2015
·
Nicholas J. Short
, Guillermo Garcia-Manero
, et al.
·
Blood
·
10
A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium
2016
·
Elias J. Jabbour
, Nicholas J. Short
, et al.
·
Blood
·
4
Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy
2013
·
Aziz Nazha
, Guillermo Garcia-Manero
, et al.
·
Blood
·
4
Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
2021
·
Naveen Pemmaraju
, Kapil N. Bhalla
, et al.
·
Blood
·
3
Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia
2020
·
Nicholas J. Short
, Tapan M. Kadia
, et al.
·
Blood
·
2
Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS)
2014
·
Elias Jabbour
, Koji Sasaki
, et al.
·
Blood
·
2
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine
2022
·
Kunhwa Kim
, Alexandre Bazinet
, et al.
·
Leukemia Research
·
1
Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome
2019
·
Kelly S. Chien
, Mahesh Swaminathan
, et al.
·
Blood
·
1
Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy
2016
·
Elias J. Jabbour
, Hagop M. Kantarjian
, et al.
·
Blood
·
1
Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS)
2015
·
Guillermo Montalban-Bravo
, Guillermo Garcia-Manero
, et al.
·
Blood
·
1
Clinical Trial Protocol S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2025
·
Jayastu Senapati
, Warren C. Fiskus
, et al.
Supplementary Table S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2025
·
Jayastu Senapati
, Warren C. Fiskus
, et al.
Supplementary Table S2 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2025
·
Jayastu Senapati
, Warren C. Fiskus
, et al.
Data from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2023
·
Jayastu Senapati
, Warren C. Fiskus
, et al.
Supplementary Table S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2023
·
Jayastu Senapati
, Warren C. Fiskus
, et al.
Supplementary Table S2 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2023
·
Jayastu Senapati
, Warren C. Fiskus
, et al.
Supplementary Table S2 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2023
·
Jayastu Senapati
, Warren C. Fiskus
, et al.
Supplementary Table S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2023
·
Jayastu Senapati
, Warren C. Fiskus
, et al.
Data from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2023
·
Jayastu Senapati
, Warren C. Fiskus
, et al.
Clinical Trial Protocol S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2023
·
Jayastu Senapati
, Warren C. Fiskus
, et al.
Clinical Trial Protocol S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2023
·
Jayastu Senapati
, Warren C. Fiskus
, et al.
Show more works
View as search
Works count:
27
Citation count:
208
H-index:
5
I10-index:
5
Year
Topic
Type
